Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Cianna Medical launches SAVI Sisters program to educate about breast cancer treatment options

Cianna Medical, Inc., the maker of the SAVI breast brachytherapy applicator, today announced the launch of SAVI Sisters, a program designed to provide education about breast cancer treatment options, primarily through social networking.

24 Sep 2010

CIC proposes criteria to improve endpoints for cancer immunotherapy trials

The Cancer Research Institute (CRI) Cancer Immunotherapy Consortium (CIC), the leading global initiative in advancing the emerging field of immuno-oncology, has proposed criteria for improved endpoints for cancer immunotherapy trials, which were published online on September 8 in the Journal of the National Cancer Institute.

24 Sep 2010

AJMS journal provides research update on new infectious pathogens

Newly recognized disease-causing viruses, bacteria, and other infections are continually emerging around the world, posing difficult challenges for patient diagnosis and treatment and for public health responses. A special symposium section of the September issue of The American Journal of the Medical Sciences (AJMS), official journal of the Southern Society for Clinical Investigation, provides a research update on important new infectious pathogens.

24 Sep 2010

FDA grants clearance for HPβCD treatment for Niemann Pick Type C disease

Children's Hospital & Research Center Oakland announced today that the US Food and Drug Administration (FDA) has granted clearance of an Investigational New Drug (IND) application to introduce Trappsol Cyclo (Hydroxypropyl Beta Cyclodextrin or HPβCD) into the brains of six year old identical twin girls dying of a rare brain-destroying cholesterol disease called Niemann Pick Type C (NPC).

24 Sep 2010

Biothera receives SBIR award to evaluate therapeutic potential of Imprime PGG drug in pancreatic cancer

Biothera has received a National Cancer Institute SBIR award to evaluate the therapeutic potential of its drug candidate Imprime PGG in pancreatic cancer, the company announced today.

24 Sep 2010

Zalicus presents synergistic drug data at Targeted Cancer Therapies World Europe 2010 meeting

Zalicus Inc. presented data today on its discovery of novel synergistic drug combinations for the treatment of cancer at the Targeted Cancer Therapies World Europe 2010 meeting in Zurich on September 23, 2010.

24 Sep 2010

FDA grants ZIOPHARM's darinaparsin Orphan Drug Designation for peripheral T-cell Lymphoma treatment

ZIOPHARM Oncology, Inc. announced today that the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to darinaparsin (Zinapar™ or ZIO-101) for the treatment of peripheral T-cell Lymphoma (PTCL). The United States Orphan Drug Act of 1983 was created to provide incentives for companies to develop and market treatments for diseases or conditions affecting fewer than 200,000 people in the United States.

23 Sep 2010

Athersys presents MultiStem phase I study results at TCT Conference

Athersys, Inc. announced at its presentation at the Transvascular Cardiovascular Therapeutics (TCT) Conference held in Washington, D.C., updated results from its phase I clinical trial of MultiStem, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI).

23 Sep 2010

New iPhone application for breast cancer patients

Nonprofit Breastcancer.org has launched an iPhone application for breast cancer patients. The Breast Cancer Diagnosis Guide is a free mobile app that walks users through the breast cancer pathology report a vital report that sets the patient's treatment path.

23 Sep 2010

Asuragen announces results of study evaluating RNA-based assay for detection of common NPM1 mutations

Asuragen, Inc. announced today the results of a collaborative study with scientists at Johns Hopkins University School of Medicine evaluating a RNA-based assay for the rapid, sensitive and multiplex detection of common NPM1 mutations. The study results were published in the September issue of the Journal of Molecular Diagnostics.

23 Sep 2010

Novartis applauds declaration of CML Awareness Day in Canada

Today is a meaningful milestone for chronic myelogenous leukemia (CML) patients and their families.

23 Sep 2010

Phase II study: Fostamatinib improves outcomes in RA patients

AstraZeneca's new oral syk inhibitor, fostamatinib (R788), recently in-licensed from Rigel Pharmaceuticals, Inc., significantly improved outcomes of patients with rheumatoid arthritis who responded inadequately to ongoing treatment with methotrexate, according to phase II study data published in The New England Journal of Medicine today.

23 Sep 2010

NCI selects Caliper's Quantum FX microCT system to study tumor models in lung cancer

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today announced that the National Cancer Institute has purchased Caliper's Quantum FX, a stand-alone microCT system for pre-clinical imaging, to study spontaneous tumor models in lung cancer.

23 Sep 2010

Revolutionary technology 'cooks' brain tumor

University Hospitals (UH) Case Medical Center is offering new hope for patients with inoperable brain tumors or lesions previously diagnosed as untreatable through a revolutionary technology called AutoLITT which "cooks" brain tumors with an MRI-guided laser. UH becomes one of only three medical centers in the world offering AutoLITT as part of its arsenal in the fight against cancer. It is especially effective in treating glioblastoma, one of the most aggressive and difficult-to-treat brain cancers.

23 Sep 2010

FDA and EMA accept regulatory submissions of vandetanib for advanced medullary thyroid cancer

AstraZeneca today announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted regulatory submissions for review of the investigational drug vandetanib in the treatment of patients with advanced medullary thyroid cancer (MTC). The FDA also granted priority review status for the new drug application and set a Prescription Drug User Fee Act (PDUFA) action date of 7 January 2011.

23 Sep 2010

Signal Genetics, Array BioPharma partner to advance personalized medicine in multiple myeloma

Signal Genetics, a privately held predictive genetic testing company focused on oncology, today announced the company will work with Array BioPharma to help push forward both companies' goals of markers for patient selection, helping bring personalized medicine and companion diagnostics to patients with multiple myeloma, a cancer of the bone marrow and antibody producing cells.

23 Sep 2010

Merck expands patient assistance programs to provide medicines to needy people

Today, Merck announced that it has significantly expanded the number of Merck medicines available through its Merck Helps patient assistance programs, which include the Merck Patient Assistance Program, the Merck Vaccine Patient Assistance Program, the ACT Program for Oncology and Hepatitis C medicines, and the SUPPORT Program for HIV/AIDS medicines.

23 Sep 2010

RXi, EyeGate collaborate to develop RNAi therapeutics for retinal disorders

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutics, and EyeGate Pharma, the leader in non-invasive ocular drug delivery announced today that they will collaborate on the ocular delivery of RNAi therapeutics. Each party will contribute technology, expertise, and resources to the collaboration.

23 Sep 2010

FDA approves Roche's COBAS AmpliPrep / COBAS TaqMan HBV Test v2.0

Roche Molecular Diagnostics announced today that the U.S. Food & Drug Administration (FDA) has approved the COBAS® AmpliPrep / COBAS® TaqMan® HBV Test v2.0 for use in the United States. The new Roche test provides a fully automated solution for the quantitative detection of hepatitis B virus (HBV) DNA in human plasma or serum for patients on HBV antiviral therapy.

23 Sep 2010

Mitsui Ventures invests US$5 million to support S*BIO's clinical program

S*BIO Pte Ltd today announced a US$5 million investment by Mitsui Ventures that will support the continued development of S*BIO's clinical programs.

23 Sep 2010

Oncology News and Research

Further Reading

Cianna Medical launches SAVI Sisters program to educate about breast cancer treatment options

CIC proposes criteria to improve endpoints for cancer immunotherapy trials

AJMS journal provides research update on new infectious pathogens

FDA grants clearance for HPβCD treatment for Niemann Pick Type C disease

Biothera receives SBIR award to evaluate therapeutic potential of Imprime PGG drug in pancreatic cancer

Zalicus presents synergistic drug data at Targeted Cancer Therapies World Europe 2010 meeting

FDA grants ZIOPHARM's darinaparsin Orphan Drug Designation for peripheral T-cell Lymphoma treatment

Athersys presents MultiStem phase I study results at TCT Conference

New iPhone application for breast cancer patients

Asuragen announces results of study evaluating RNA-based assay for detection of common NPM1 mutations

Novartis applauds declaration of CML Awareness Day in Canada

Phase II study: Fostamatinib improves outcomes in RA patients

NCI selects Caliper's Quantum FX microCT system to study tumor models in lung cancer

Revolutionary technology 'cooks' brain tumor

FDA and EMA accept regulatory submissions of vandetanib for advanced medullary thyroid cancer

Signal Genetics, Array BioPharma partner to advance personalized medicine in multiple myeloma

Merck expands patient assistance programs to provide medicines to needy people

RXi, EyeGate collaborate to develop RNAi therapeutics for retinal disorders

FDA approves Roche's COBAS AmpliPrep / COBAS TaqMan HBV Test v2.0

Mitsui Ventures invests US$5 million to support S*BIO's clinical program

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News